Healthcare active runners: Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer Inc. (NYSE:PFE), MannKind Corporation (NASDAQ:MNKD)

On Monday, Johnson & Johnson (NYSE:JNJ) announced that it accepted the binding offer from The Carlyle Group (NASDAQ:CG), which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4 Billion, subject to customary adjustments. Johnson & Johnson (NYSE:JNJ) stock performance was 0.16% in last session and finished the day at $98.42. Traded volume was 10.31million shares in the last session and the average volume of the stock remained 8.80million shares. The beta of the stock remained 0.52. Johnson & Johnson (NYSE:JNJ) insider ownership is 0.02%.

Merck & Co. Inc (NYSE:MRK) Insider Bruce N. Kuhlik sold 145,225 shares of the stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $56.43, for a total value of $8,195,046.75. Merck & Co., Inc. (NYSE:MRK) dropped -0.16 percent to $56.12 Friday on volume of 10.41million shares. The intra-day range of the stock was $56.09 to $56.72. Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $165.03billion.

Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pfizer Inc. (NYSE:PFE)’s vaccine candidate, bivalent rLP2086, currently under investigation for the prevention of invasive meningococcal disease due to Neisseria meningitidis serogroup B in persons 10 – 25 years of age. Pfizer Inc. (NYSE:PFE)’s stock on Apr 04, 2014 reported a decrease of -0.74% to the closing price of $32.16. Its fifty two weeks range is $27.12-$32.96. The total market capitalization recorded $205.62billion. The overall volume in the last trading session was 26.28million shares. In its share capital, PFE has 6.39billion outstanding shares.

Mannkind Corporation (NASDAQ:MNKD) ripped higher this week after the company announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 13 to 1 to recommend that AFREZZA® (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted marketing approval by the FDA to improve glycemic control in adults with type 2 diabetes. On Friday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -0.87% to close the day at $6.87. Company monthly performance is recorded as 20.32%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 27.22%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone